Munch 2021.

Methods	Trial design: quadruple blinded, multi‐centre RCT Sample size: 1000 Setting: inpatient Language: English Number of centres: 14 Type of intervention (treatment/prevention): treatment
Participants	Inclusion criteria Aged ≥ 18 years or above AND Confirmed SARS‐CoV‐2 (COVID‐19) requiring hospitalisation AND Use of one of the following: IMV OR NIV or continuous use CPAP for hypoxia OR oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system Exclusion criteria  Use of systemic corticosteroids for any other indication than COVID‐19 IMV for > 48 h Invasive fungal infection Fertile woman (< 60 years of age) with positive urine human gonadotropin (hCG) or plasma‐hCG Known hypersensitivity to hydrocortisone A patient for whom the clinical team has decided not to use IMV Previously randomised into the COVID STEROID trial Informed consent not obtainable
Interventions	Details of intervention Dose: hydrocortisone continuous infusion: 200 mg (104 mL) every 24 h, bolus injections: 50 mg (10 mL) every 6 h, total treatment duration: 7 days Route of administration: IV Treatment details of control group (e.g dose, route of administration):  sodium chloride 9 mg/mL continuous infusion: 104 mL every 24 h, bolus injections: 10 mL every 6 h, total treatment duration: 7 days Concomitant therapy: no information
Outcomes	Primary study outcome: days alive without life support (i.e. IMV, circulatory support or renal replacement therapy) from randomisation to day 28
Notes	Recruitment status: active, not recruiting Prospective completion date: 8 June 2021 Date last update was posted: 9 March 2021 Sponsor/funding: Scandinavian Critical Care Trials Group